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Abstract 
Background: We previously reported on the change in the use of rosiglitazone-containing products (RCP) and 
adverse event reporting rates in Canadian patients between 2004 and 2010. The present study extends this analysis to 
include the January 2011 to December 2012 time period.
Methods: RCP utilization rates were obtained from IMS Health Brogan’s longitudinal de-identified patient database, 
LRx. GlaxoSmithKline’s global adverse events database was used to extract adverse events (AE), serious adverse events 
(SAE), and cardiac adverse events (CAE) reported in Canadian patients receiving RCP from April 2004 to December 
2012. The patient utilization information from the LRx database was used to estimate rates per 100,000 patients.
Results: An estimated 182,841 patients were dispensed RCP prescriptions between April 2004 and December 2012. 
The total number of patients using RCP decreased by 85 % from 2011 to 2012. From its peak use in 2007, the number 
of patients filling a prescription decreased 97 %. A total of 1069 AEs were reported during the study period, of which 
32 AE’s were reported from Jan 2011 to Dec 2012. The average monthly reporting rates of AE’s, SAE’s and CAE’s over 
2011–2012 were 10.8/100,000 patients, 9.1/100,000 patients and 5.0/100,000 patients, respectively.
Conclusions: The utilization of RCP in Canada has significantly declined. The significance of the adverse event rate 
information presented is uncertain and must be evaluated within the context of the well known factors that can influ-
ence AE reporting rates, as well as limitations to the methods used to estimate these reporting rates.
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Background
Rosiglitazone, a member of the thiazolidinedione class 
of oral anti-diabetic agents, improves glycemic control 
in patients with type 2 diabetes mellitus by improving 
insulin sensitivity, decreasing insulin resistance and low-
ering blood glucose levels. In May 2007, the publication 
of a meta-analysis evaluating the effect of rosiglitazone 
on cardiovascular morbidity and mortality generated 
significant public attention. The analysis found rosigli-
tazone treatment was associated with a statistically sig-
nificant increased risk of myocardial infarction (OR 1.43, 
CI 1.03–1.98) in comparison with the use of placebo or 
other anti-diabetic agents [1].
Results from Rosiglitazone Evaluated for Cardiovas-
cular Outcomes and Regulation of Glycemia in Diabetes 
(RECORD), a long term cardiovascular outcomes trial, 
became available in 2009 [2]. In contrast with the find-
ings of the 2007 meta-analysis, this trial’s results found 
no increased risk of cardiovascular death, myocardial 
infarction or stroke associated with RCP use compared 
with standard glucose-lowering drugs in people with type 
2 diabetes mellitus [2].
At the request of the United States (US) Food and Drug 
Administration (FDA), an independent comprehensive, 
expert re-evaluation of the RECORD data was con-
ducted by the Duke Clinical Research Institute (DCRI). 
The readjudicated results assessed rosiglitazone versus 
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the standard-of-care diabetes drugs metformin and sul-
fonylurea and confirmed the original RECORD findings 
[3]. In November 2013, after an extensive review of the 
RECORD trial and other data, the FDA concluded that 
there is no statistically significant difference between 
rosiglitazone and older diabetes drugs with respect to 
the risk of death or major adverse cardiovascular out-
comes, other than the known class effect of heart failure 
[4]. This conclusion led the FDA to require GlaxoSmith-
Kline (GSK) to remove the boxed warning on myocardial 
infarction in the US rosiglitazone label information, to 
substantially lift the restrictions on distribution of rosigl-
itazone-containing products, and to modify the US risk 
evaluation and mitigation strategy (REMS) program and 
Medication Guide.
In Canada, following publication of the 2007 meta-
analysis, and before the results of RECORD were avail-
able and readjudicated, two Health Canada-endorsed risk 
communications were released [5, 6]. The first risk com-
munication, in June 2007, provided information about 
the meta-analysis and discussed rosiglitazone benefit-
risk treatment considerations [5]. The second risk com-
munication, in November 2007, provided additional 
information and introduced restrictions on the use of 
AVANDIA® (rosiglitazone), AVANDAMET® (rosiglita-
zone and metformin), and AVANDARYL® (rosiglitazone 
and glimepiride) [6].
Subsequent to the meta-analysis’ publication and these 
first two Health Canada-endorsed risk communications, 
several authors reported a marked decline in the utili-
zation of RCP in Canada [7–10] These reports included 
an analysis by Rawson and Terres, which evaluated the 
impact of these risk communications on the change in 
use of RCP as monotherapy or as part of triple or tri-
ple-plus combination therapy between April 2004 and 
December 2010, as well as an analysis of the rates of over-
all adverse events (AEs), serious adverse events (SAEs) 
and cardiac AEs before and after the introduction of the 
November 2007 prescribing changes [9]. That publica-
tion noted that it was not possible to determine whether 
the decline in prescriptions was attributable to the pub-
lication of the meta-analysis, the changes in prescribing 
guidelines, media attention or a combination of these 
factors.
In November 2010, a third Health Canada-endorsed 
risk communication was released [11]. This communi-
cation introduced further restrictions on the use of RCP 
for the treatment of type 2 diabetes mellitus in Canada 
and required that physicians document the eligibility 
of patients as per rosiglitazone’s updated label, counsel 
patients on the benefits-risks of rosiglitazone treatment, 
including the cardiovascular risks, and obtain their writ-
ten informed consent prior to starting or renewing a 
prescription for a RCP. Building upon the previous find-
ings of Rawson and Terres, and as part of GSK’s ongoing 
regulatory commitment to Health Canada, the objec-
tive of the present study was to report on the change 
in RCP utilization patterns and reporting rates of AEs 
and cardiac AEs in Canada following this third risk 
communication.
Methods
The methods for the present analysis are consistent with 
those described in a previous study on RCP utilization 
and adverse event rates in Canada [9]. Briefly, a cross-sec-
tional ecological study in patients dispensed RCP in Can-
ada was conducted. The study population was defined as 
patients dispensed RCP in Canada between April 1, 2004 
and December 31, 2012, based on IMS Brogan Health’s 
longitudinal de-identified patient database, LRx. At the 
time of this updated analysis, the LRx database contained 
approximately 200 million prescriptions for over 20 
million patients, representing a capture of 74  % of pre-
scriptions nationally [12]. As per IMS Health Brogan’s 
practice when performing LRx drug utilization studies, 
patients with inconsistent gender or age labels, who had 
only one rosiglitazone prescription from a pharmacy, 
had unreasonably high numbers of prescriptions (i.e. the 
numbers of prescriptions dispensed were extremely high 
and inconsistent with typical treatment patterns), and 
patients who filled prescriptions at pharmacies that had 
not consistently reported data to IMS Health Brogan for 
the past 7  years were excluded. Proportional allocation 
methods established by IMS Brogan Health, which uti-
lize an additional IMS Brogan Health data source, Com-
puScript, were employed to estimate RCP utilization in 
the overall Canadian population. The number of patients 
receiving any rosiglitazone product per calendar month 
was estimated. Overall RCP utilization per month, as well 
as its use in monotherapy, dual combination therapy, or 
triple-plus combination therapy was estimated.
Estimated rates of AEs, serious AEs (SAEs) and car-
diac AEs per 100,000 Canadian patients for the analysis 
period of April 1, 2004 to December 31, 2012 were cal-
culated using Canadian AEs reported to GSK’s global 
adverse event reporting database during this timeframe 
as the numerator and the updated IMS-derived number 
of rosiglitazone patients as the denominator. GSK’s global 
adverse event reporting database uses the Medical Dic-
tionary for Regulatory Activities (MedDRA), which is a 
clinically validated international medical terminology 
dictionary used by regulatory authorities in the phar-
maceutical industry, to classify adverse events [13, 14]. 
Adverse events reported to involve the cardiac system 
(e.g. myocardial infarction, cardiac failure, hyperten-
sion, pericardial effusion, cardiac operation) receive a 
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MedDRA “cardiac disorder” system organ classification 
within GSK’s global adverse event database, and were 
reported as cardiac adverse events in the present study.
Results
Of the 241,806 patients identified as having received at 
least one RCP prescription between April 1, 2004 and 
December 31, 2012, 58,965 met IMS Health Brogan’s 
exclusion criteria. Accordingly, an estimated 182,841 
patients were dispensed RCP prescriptions over this time 
period. The extension of this analysis to December 2012 
resulted in the inclusion of an additional 1905 patients 
from the 2004–2010 analysis, which reported on a total 
of 180,936 patients [9].
The monthly utilization of RCP, overall and as mono-
therapy, dual combination therapy or triple-plus combi-
nation therapy, between April 2004 and December 2012 
is presented in Fig. 1. The total number of patients dis-
pensed a RCP prescription in Canada decreased by 85 %, 
from 43,774 patients in January 2011 to 6349 patients in 
December 2012. This represents a total decrease of 97 % 
from their peak utilization by 190,840 patients in May 
2007. The decrease in RCP utilization was consistent 
across the treatment patterns studied, with rosiglitazone 
use as monotherapy, in dual therapy or triple-plus com-
bination therapy falling by 84, 86 and 85 %, respectively, 
over the January 2011 to December 2012 time period, 
and by 97, 97 and 96 %, respectively, from their peak uti-
lization in May 2007.
Between April 2004 and December 2012, a total of 1069 
Canadian AE reports in RCP recipients were identified 
from GSK’s AE database, of which 32 AEs were reported 
in the January 2011 to December 2012 time period. The 
estimated monthly rates of AEs, SAEs and cardiac AEs, 
per 100,000 patients, for the April 2004 to October 
2007, November 2007 to December 2010, and January 
2011 to December 2012 time periods are provided in 
Table  1. Estimated monthly rates of AE’s declined from 
13.1/100,000 patients in April 2004–October 2007 to 
5.6/100,000 patients in November 2007–December 2010. 
The rate subsequently rose to 10.8/100,000 patients in 
January 2011–December 2012. A similar pattern of SAE’s 
and cardiac AE’s was observed throughout the three time 
periods.
Discussion
The results of this RCP utilization analysis show an 
85  % decrease in RCP utilization between January 2011 
and December 2012. This decline may be attributable 
to the November 2010 Health Canada-endorsed com-
munication and the subsequent introduction of further 
restrictions on the use of RCP for the treatment of type 
2 diabetes mellitus as well as the implementation of the 
requirement for patient informed consent. The overall 
Canadian decline in rosiglitazone utilization from May 
2007 to December 2012 is similar to the findings of stud-
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Fig. 1 Number of patients receiving a rosiglitazone-containing product (RCP) by month, April 2004 to December 2012
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The estimated adverse event reporting data must be 
considered in the context of several important limita-
tions to the methodology employed to estimate these 
rates. In contrast to clinical trials where adverse events 
are proactively collected, passive AE reporting sys-
tems suffer from an indeterminate degree of reporting 
bias. Many factors can influence adverse event report-
ing rates, such as actual or anticipated litigation and 
publicity surrounding a type of event. These factors 
can cause under-reporting and/or over-reporting bias. 
Another limitation of passive AE reporting systems is 
the lack of a denominator with which to calculate rates. 
In the absence of a denominator, RCP prescription data 
was utilized in the estimation of AE, SAE and cardiac 
AE rates. As a result, the adverse event reporting rate 
data provided may suffer from measurement bias. In 
addition, given the retrospective nature of this analy-
sis, the potential impact of the implementation of the 
patient informed consent requirement following the 
November 2010 risk communication on changes in 
adverse event reporting behaviour of RCP recipients to 
GSK’s AE database, in comparison with their reporting 
behaviours prior to the implementation of the patient 
informed consent requirement, is unknown.
In the context of type 2 diabetes mellitus, there is an 
established increased risk of major cardiovascular com-
plications and mortality, in comparison with people 
without diabetes mellitus [26, 27]. Results from an anal-
ysis of all-cause mortality among individuals with and 
without diabetes in the Framingham Heart study found 
that mortality rates are approximately twofold higher 
amongst individuals with diabetes mellitus compared to 
individuals without diabetes mellitus [26]. Similarly, the 
findings of collaborative meta-analysis of 102 prospec-
tive studies reported a twofold higher risk for a wide 
range of vascular diseases in people with diabetes in 
comparison with those without diabetes mellitus [27].
Consistent with RECORDs findings, the results of an 
analysis of RCP use and cardiovascular outcomes in the 
Veteran Affairs Diabetes Trial found that the use of rosigli-
tazone was associated with decreased risk of the primary 
cardiovascular composite outcome (myocardial infarction, 
cardiovascular death, stroke, congestive heart failure, inva-
sive revascularization, inoperable coronary artery disease 
and amputation for ischemia) and cardiovascular death, 
and did not lead to a higher risk of myocardial infarc-
tion [28]. Similarly, an evaluation of patients with type 2 
diabetes mellitus in the REACH registry found the use of 
thiazolidinediones was not associated with increased inci-
dence of major cardiovascular events [29]. The results of 
the BARI 2D trial also support the RECORD findings [30].
Conclusion
The results of this analysis show a substantial decrease 
in rosiglitazone utilization over the January 2011 to 
December 2012 period. A total of 32 adverse events 
in Canadian rosiglitazone recipients were reported to 
GSK’s global adverse event database during this time 
period with an average reporting rate of 10.8 events per 
100,000 patients. Given the limitations of the method-
ology employed to evaluate reporting rates of adverse 
events, as well as other noted factors potentially impact-
ing the reporting rate, the significance of this finding is 
limited.
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Table 1 Estimated average monthly rates of adverse events per 100,000 patients in three time periods
a Of the adverse events this row accounts for the serious adverse events
b Of the serious adverse events this row accounts for the cardiac adverse events
April 2004–October 2007 November 2007–December 2010 January 2011–December 2012
Average Min/max 95 % CI Average Min/max 95 % CI Average Min/max 95 % CI
Adverse events 13.1 2.3/26.9 8.4–20.4 5.6 0.0/12.1 2.3–13.4 10.8 0.0/42.9 2.0–59.2
Serious adverse eventsa 5.9 0.6/21.1 3.1–11.3 3.3 0.0/8.6 1.1–10.4 9.1 0.0/42.9 1.3–62.4
Cardiac adverse eventsb 2.2 0.0/9.2 0.8–6.4 2.1 0.0/6.6 0.5–8.9 5.0 0.0/20.8 0.4–65
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